Vanguard Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.36M Sell
116,975
-6,749
-5% -$181K ﹤0.01% 1477
2026
Q2
$3.13M Buy
123,724
+9,612
+8% +$211K ﹤0.01% 1332
2026
Q1
$2.54M Buy
+114,112
New +$2.73M ﹤0.01% 1341

Other funds holding ACAD

Vanguard Asset Management's ACAD Position: Q3 2026 in Review

Vanguard Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 5.5% in Q3 2026, selling an estimated $181K and leaving 116,975 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1477.

Vanguard Asset Management first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.13M in Q2 2026. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Vanguard Asset Management held 116,975 shares of Acadia Pharmaceuticals worth $2.36M as of Q3 2026.
  • Vanguard Asset Management sold 6,749 Acadia Pharmaceuticals shares in Q3 2026, an estimated $181K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1477 holding.
  • Vanguard Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Acadia Pharmaceuticals position peaked at $3.13M in Q2 2026.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.